It has been speculated that the strengthened tumor-killing effect of DCCIKs may be associated with upregulation of cytokines, such as IL-12 and IFN-γ, in DCCIKs' supernatant and with high expression of CD3+CD56+ double positive cells as well [21]. Here, NCAM1 is linked to neoplasm.